Article
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Expert review of anticancer therapy - 1 Jun 2009
Blay Jean-Yves, Reichardt Peter
Abstract excerpt
The European Society for Medical Oncology (ESMO) recommendations on the management of gastrointestinal stromal tumor (GIST) have recently been updated. Imatinib 400 mg/day remains the standard first-line treatment for patients with metastatic GIST. Mutational analysis has received a strong recommendation for diagnostic purposes. Furthermore, patients with KIT exon 9-activating mutations are now recommended to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
